Literature DB >> 9209640

Trans-rearrangements and the risk of lymphoid malignancy.

I R Kirsch1.   

Abstract

BACKGROUND: Antigen receptor 'trans-rearrangements' occur in all individuals and represent a particular type of genetic instability whose mechanism, V(D)J recombination, is the same as that required for the development of a normal immune response.
DESIGN: We have measured the level of trans-rearrangements in a variety of populations characterized by increased risk for the development of lymphoid malignancy. The human populations studied include those with an inherited predisposition to lymphomagenesis (ataxia-telangiectasia patients), as well as populations at increased risk because of an occupational (agriculture workers) or iatrogenic (Hodgkin's disease patients) exposure. In addition, we have developed a mouse model for the more controlled analysis of these events.
RESULTS: There is a correlation between the absolute number of trans-rearrangements (as a population mean or median) and risk of lymphoma, whether that risk is based on an inherited predisposition or acquired exposure.
CONCLUSION: This assay may serve as an easily measurable biomarker of lymphoma risk. If so, it is more than a fortuitous biomarker since the same mechanism responsible for the formation of trans-rearrangement is, at least in part, responsible for the majority of presumably 'malevolent' translocations associated with the transformation of lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209640

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

1.  Activation of V(D)J recombination induces the formation of interlocus joints and hybrid joints in scid pre-B-cell lines.

Authors:  S Lew; D Franco; Y Chang
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

2.  Illegitimate recombination between T cell receptor genes in humans and pigs (Sus scrofa domestica).

Authors:  Petra Musilova; Jitka Drbalova; Svatava Kubickova; Halina Cernohorska; Hana Stepanova; Jiri Rubes
Journal:  Chromosome Res       Date:  2014-07-20       Impact factor: 5.239

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.